This site is intended for healthcare professionals
  • Home
  • /
  • Journals
  • /
  • Uncategorised Disease
  • /
  • Therapeutic Oligonucleotides Targeting Liver Disea...
Journal

Therapeutic Oligonucleotides Targeting Liver Disease: TTR Amyloidosis

Read time: 1 mins
Published:29th Sep 2015
Author: Niemietz C, Chandhok G, Schmidt H.
Source: Molecules
Availability: Free full text
Ref.:Molecules. 2015 Sep 30;20(10):17944-75.
DOI:10.3390/molecules201017944
Therapeutic Oligonucleotides Targeting Liver Disease: TTR Amyloidosis


The liver has become an increasingly interesting target for oligonucleotide therapy. Mutations of the gene encoding transthyretin (TTR), expressed in vast amounts by the liver, result in a complex degenerative disease, termed familial amyloid polyneuropathy (FAP). Misfolded variants of TTR are linked to the establishment of extracellular protein deposition in various tissues, including the heart and the peripheral nervous system. Recent progress in the chemistry and formulation of antisense (ASO) and small interfering RNA (siRNA) designed for a knockdown of TTR mRNA in the liver has allowed to address the issue of gene-specific molecular therapy in a clinical setting of FAP. The two therapeutic oligonucleotides bind to RNA in a sequence specific manner but exploit different mechanisms. Here we describe major developments that have led to the advent of therapeutic oligonucleotides for treatment of TTR-related disease.


Read abstract on library site Access full article